Literature DB >> 27469377

HIV-1 replication in central nervous system increases over time on only protease inhibitor therapy.

Maximilian Donath1, Timo Wolf1, Martin Stürmer2, Eva Herrmann3, Markus Bickel4, Pavel Khaykin1, Siri Göpel1, Peter Gute4, Annette Haberl1, Philipp de Leuw1, Gundolf Schüttfort1, Annemarie Berger2, Christoph Stephan5.   

Abstract

There are concerns about central nervous system (CNS)-replication of HIV-1 in patients on boosted protease inhibitors. Purpose of this study was to compare HIV-1 viral loads (VLs) from patients treated with only boosted dual protease inhibitor (bdPI), versus combination antiretroviral therapy (cART group), containing two nucleoside analogue reverse transcriptase inhibitors (NRTI) and a third partner. All patients from a large German HIV-treatment cohort with available medication, clinical and demographic data, including results from simultaneous HIV-1 viral load (VL) assessments in cerebrospinal fluid (CSF) and blood plasma, were retrospectively evaluated as controlled cross-sectional study. CSF had been obtained from patients with variable neurological symptoms during 2005-2014. Statistical analysis comprised nonparametric tests, regression and correlation techniques accounting for undetectable quantifications. Statistical analysis comprised nonparametric tests, regression and correlation techniques accounting for undetectable quantifications. Overall, 155 patients were evaluable (bdPI: 24; cART: 131). At time of CSF-collection, both groups were comparable in age, gender, CD4-cell counts, or primary HIV-transmission risks, though bdPI patients were clinically more advanced. The proportion of patients with undetectable HIV-1 (<50 copies/ml) in CSF was lower for bdPI group (25 vs 49.6 %; p = 0.026), but similar in plasma (46 vs 41 %). Median CSF-VL was higher in bdPI group (600 vs 50 copies/ml; p = 0.027) and similar in plasma. Mean VL CSF/plasma ratio was 342.91 for bdPI- and 54.48 for cART patients (p < 0.001). Pearson's regression analysis revealed a trend for an elevated VL-ratio over time within bdPI group. HIV-1 replication was higher and more frequently detectable in CSF from bdPI patients, indicating a worse CNS penetration effectiveness of used boosted PI. Within bdPI group, measured CNS-viral replication was increasing over time, suggesting an over time impaired HIV-1 suppression in CSF.

Entities:  

Keywords:  Blood–brain barrier; HIV persistence; HIV reservoir; Low-level replication; Protease inhibitor therapy; Viral escape

Mesh:

Substances:

Year:  2016        PMID: 27469377     DOI: 10.1007/s00430-016-0469-7

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  34 in total

1.  HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey.

Authors:  Muammer Osman Köksal; Hayati Beka; Nadine Lübke; Jens Verheyen; Haluk Eraksoy; Atahan Cagatay; Rolf Kaiser; Baki Akgül; Ali Agacfidan
Journal:  Med Microbiol Immunol       Date:  2015-04-28       Impact factor: 3.402

2.  Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load.

Authors:  Armelle Pasquet; Faiza Ajana; Hugues Melliez; Caius Giurca; Julien Poissy; Yazdan Yazdanpanah
Journal:  AIDS       Date:  2012-08-24       Impact factor: 4.177

3.  Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).

Authors:  José R Arribas; Federico Pulido; Rafael Delgado; Alicia Lorenzo; Pilar Miralles; Alberto Arranz; Juan J González-García; Concepción Cepeda; Rafael Hervás; José R Paño; Francisco Gaya; Antonio Carcas; María L Montes; José R Costa; José M Peña
Journal:  J Acquir Immune Defic Syndr       Date:  2005-11-01       Impact factor: 3.731

4.  Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.

Authors:  Jean-Luc Meynard; Vincent Bouteloup; Roland Landman; Philippe Bonnard; Vincent Baillat; André Cabie; Sami Kolta; Jacques Izopet; Anne-Marie Taburet; Patrick Mercie; Geneviève Chene; Pierre-Marie Girard
Journal:  J Antimicrob Chemother       Date:  2010-09-15       Impact factor: 5.790

5.  Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

Authors:  Christine Katlama; Marc A Valantin; Michele Algarte-Genin; Claudine Duvivier; Sidonie Lambert-Niclot; Pierre M Girard; Jean M Molina; Bruno Hoen; Sophie Pakianather; Gilles Peytavin; Anne G Marcelin; Philippe Flandre
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

6.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

Review 7.  Is there a higher risk of CNS adverse events for PI monotherapy versus triple therapy? A review of results from randomized clinical trials.

Authors:  William Powderly; Andrew Hill; Christiane Moecklinghoff
Journal:  HIV Clin Trials       Date:  2014 May-Jun

8.  Exact and Asymptotic Weighted Logrank Tests for Interval Censored Data: The interval R package.

Authors:  Michael P Fay; Pamela A Shaw
Journal:  J Stat Softw       Date:  2010-08       Impact factor: 6.440

9.  Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Authors:  Ana Canestri; François-Xavier Lescure; Stephane Jaureguiberry; Antoine Moulignier; Corinne Amiel; Anne Geneviève Marcelin; Gilles Peytavin; Roland Tubiana; Gilles Pialoux; Christine Katlama
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

10.  The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL.

Authors:  Andrea Antinori; Jose Arribas; Jan Fehr; Pierre-Marie Girard; Andrzej Horban; Andrew Hill; Yvon van Delft; Christiane Moecklinghoff; Andrew Hill
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

View more
  6 in total

1.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Authors:  Saverio G Parisi; Samantha Andreis; Monica Basso; Silvia Cavinato; Renzo Scaggiante; Marzia Franzetti; Massimo Andreoni; Giorgio Palù; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2017-09-01       Impact factor: 3.402

2.  Incidence of symptomatic CSF viral escape in HIV infected patients receiving atazanavir/ritonavir (ATV/r)-containing ART: a tertiary care cohort in western India.

Authors:  Atul K Patel; Ketan K Patel; Swati Gohel; Ambuj Kumar; Scott Letendre
Journal:  J Neurovirol       Date:  2018-04-24       Impact factor: 2.643

Review 3.  Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants.

Authors:  Shih-Ping Lin; Andrea Calcagno; Scott L Letendre; Qing Ma
Journal:  Curr Top Behav Neurosci       Date:  2021

4.  HIV-1 persistent viremia is frequently followed by episodes of low-level viremia.

Authors:  Marek Widera; Miriam Dirks; Barbara Bleekmann; Robert Jablonka; Martin Däumer; Hauke Walter; Robert Ehret; Jens Verheyen; Stefan Esser
Journal:  Med Microbiol Immunol       Date:  2017-02-20       Impact factor: 3.402

5.  Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA.

Authors:  Jeymohan Joseph; Paola Cinque; Deborah Colosi; Ameet Dravid; Luminita Ene; Howard Fox; Dana Gabuzda; Magnus Gisslen; Sarah Beth Joseph; Scott Letendre; Shibani S Mukerji; Avindra Nath; Ignacio Perez-Valero; Deborah Persaud; Richard W Price; Vasudev R Rao; Ned Sacktor; Ronald Swanstrom; Alan Winston; Valerie Wojna; Edwina Wright; Serena Spudich
Journal:  J Virus Erad       Date:  2016-10-05

Review 6.  Human Immunodeficiency Virus in the Brain-Culprit or Facilitator?

Authors:  Luminita Ene
Journal:  Infect Dis (Auckl)       Date:  2018-02-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.